1. Home
  2. ESTA vs KOD Comparison

ESTA vs KOD Comparison

Compare ESTA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

HOLD

Current Price

$87.84

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$41.66

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTA
KOD
Founded
2004
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
ESTA
KOD
Price
$87.84
$41.66
Analyst Decision
Strong Buy
Buy
Analyst Count
7
7
Target Price
$86.86
$35.43
AVG Volume (30 Days)
767.0K
830.9K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
42.67
N/A
EPS
N/A
N/A
Revenue
$61,208,000.00
N/A
Revenue This Year
$28.05
N/A
Revenue Next Year
$26.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
76.49
N/A
52 Week Low
$33.35
$4.39
52 Week High
$92.84
$47.84

Technical Indicators

Market Signals
Indicator
ESTA
KOD
Relative Strength Index (RSI) 59.49 63.03
Support Level $63.71 $39.37
Resistance Level N/A $46.72
Average True Range (ATR) 3.84 3.05
MACD -0.46 0.67
Stochastic Oscillator 62.64 96.33

Price Performance

Historical Comparison
ESTA
KOD

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: